Skip to content
Subscriber Only

Goldman Sachs-Backed InferVision Picks Banks for Hong Kong IPO

  • CSC Financial, Goldman Sachs and UBS are working on the IPO
  • InferVision looking to raise about $300 million in share sale
InferRead-CT

Source: InferVision AI

InferVision, a medical artificial intelligence technology provider, has picked banks to work on its Hong Kong initial public offering which could raise about $300 million, according to people familiar with the matter.

The company is working with CSC Financial Co., Goldman Sachs Group Inc. and UBS Group AG on the planned listing, the people said, asking not to be identified as the information is private. The firm, which counts Goldman Sachs Asset Management and Qiming Venture Partners among its backers, could start its share sale as soon as this year, the people said.